Tuesday, October 13, 2026

Corporate Risk Assessment

2 articles

IDEX Faces Catastrophic Export Control Risk From Mott Corp. Acquisition

IDEX Faces Catastrophic Export Control Risk From Mott Corp. Acquisition

IDEX's September 2024 acquisition of Mott Corp. has introduced a regulatory exposure rated catastrophic in severity. Mott's advanced porous metal and filtration technologies overlap with product categories governed by U.S. export control law, including EAR and ITAR. IDEX's global operations create pathways through which controlled technologies could reach restricted parties or sanctioned jurisdictions.

LM Salvado•
Alliance Resource Partners faces stranded asset risk as coal phase-out accelerates across four-state footprint

Alliance Resource Partners faces stranded asset risk as coal phase-out accelerates across four-state footprint

Alliance Resource Partners, L.P., the Tulsa-based coal MLP, confronts medium-probability catastrophic risk from energy transition rendering its Illinois, Indiana, Kentucky, and West Virginia mining complexes obsolete. The assessment carries 70% confidence as utilities accelerate coal plant retirements ahead of schedule. Stranded asset exposure threatens the partnership's debt service capacity and unitholder distributions.

ViaNews Editorial Team (Finance)•
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,372 source documents archived
Query this data → isubstrate.com